Protocol Number: 89-N-0045

Title:

Evaluation of Progression in Multiple Sclerosis by Magnetic Resonance Imaging (MRI)

Number:

89-N-0045

Summary:

Magnetic Resonance Imaging (MRI) is an advanced form of X-ray that uses magnetism to create pictures with excellent anatomical resolution. MRI is especially useful when studying the brain and nervous system.

One type of MRI is done after a drug called gadolinium is injected into the vein. Gadolinium does not usually crossover from the bloodstream into the brain. However, when it does cross it can be seen by MRI. Therefore, when gadolinium is detected by MRI it means there has been some disruption of the barrier that normally exists between the blood and the brain. Researchers believe that a change in the blood-brain barrier is the first step in the development of new MS lesions.

The overall goals of the study are to identify immunological processes that may contribute to the development of Multiple Sclerosis and to design specific therapies for the disease.

Sponsoring Institute:

National Institute of Neurological Disorders and Stroke (NINDS)

Recruitment Detail

Type: Active Accrual Of New Subjects

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): Children

Eligibility Criteria:

INCLUSION CRITERIA:

Diagnosis of MS based on combined MRI and clinical crtieria OR, presenation with a clinically isolated syndrome consistent with MS and at least 2 abnormalities on MRI consistent with MS.

18-60 years of age

Not currently receiving therapy for MS

Able to give informed consent

EXCLUSION CRITERIA:

Diagnosis of neurological disease other than MS

Significant medical condition other than MS

Contraindication for MRI

Pregnancy

Special Instructions: Currently Not Provided

Keywords:

Multiple Sclerosis

Magnetic Resonance Imaging

Recruitment Keywords:

None

Conditions:

Multiple Sclerosis

Investigational Drug(s):

None

Investigational Device(s):

None

Contacts:

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citations:

Clinical safety of serial monthly administrations of gadopentetate dimeglumine in patients with multiple sclerosis: implications for natural history and early-phase treatment trials

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI

Increases insoluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Networks and Applications, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

Warren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/15/2004